| Name | Title | Contact Details |
|---|---|---|
Zhuodan Jin |
Chief Human Resources Officer | Profile |
Cathleen Lowndes |
Chief Human Resources Officer | Profile |
Cathleen Lowndes |
Chief Human Resources Officer | Profile |
Quantum Medical Imaging is a Ronkonkoma, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vermillion`s vision is to become a recognized leader in the advancement of women`s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases. We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.
Parallax Medical, Inc. is a Austin, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
For almost half a century, Merry X-Ray (MXR) Corporation has met the challenges of keeping pace with the rapidly changing technology within the medical imaging profession. Most dramatic of these changes has been the migration from analog imaging to